Drugs / DS-6157a
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04276415 | May 2020 → Mar 2022 | gastrointestinal stromal tumor | Daiichi Sankyo | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DS-6157a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04276415 ↗ |
| Modality | Other / unclassified | “antibody-drug conjugate (ADC)” NCT04276415 ↗ |
| Route | Intravenous | “Administered as a single agent intravenously (IV) every 3 weeks” NCT04276415 ↗ |